Project CBD

JANUARY 24, 2019

In his first article of the new year, Raphael Mechoulam and other Israeli scientists look at the “real life experiences of medical cannabis treatment in autism.” Around 10-20% of patients stopped taking various medications (mostly antipsychotic and antiepileptic drugs) within 6 months of starting cannabis treatment.

Research and Development 252

Research and Development Chronic Pain Cannabinoids Treatment 252

Cannabis Law Report

AUGUST 10, 2021

Enters into the Chronic Pain Market with Psychedelics. binding letter of intent signed on July 12th 2021 to purchase certain assets of Cannvalate Pty Ltd. (“Shanti”), and all its assets focused on psychedelic MDMA-based drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5%

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. About RYAH Group, Inc. RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

CannaMD

NOVEMBER 4, 2020

Cannabis has been used for centuries to manage chronic pain from all sources and, as a recent study highlights, its positive effects extend to migraines. Read on to learn how medical marijuana helps migraines and headaches, and why neurologists are increasingly optimistic about this non-traditional treatment! The results?

Patients 105

Patients Chronic Pain Marijuana Research and Development 105

Veriheal

AUGUST 7, 2022

New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).

Consumption 109

Consumption Patients Research and Development Data 109

Veriheal

DECEMBER 28, 2021

Over the last few decades, the cannabis plant and its many components have been the focal point of research and stiff debate. D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

Sensi Seeds

DECEMBER 10, 2018

At the same time, research on medical cannabis over the past two decades has not ceased to increase and provide evidence of the plant’s medical value. As a result, medical and scientific research has been highly constrained for many decades. Exponential Increase in Cannabis Research: Trends.

Medicine 81

Medicine Research and Development Data Policy 81

PrestoDoctor

SEPTEMBER 6, 2023

Codeine works by binding to opioid receptors in the brain, blocking pain signals and providing a sense of relief. Traditionally, prescription codeine has been prescribed for a variety of conditions, including post-operative pain, dental procedures, and chronic pain.

Chronic Pain 105

Chronic Pain Research and Development Patients Cannabis 105

Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future. About Delic Corp, Inc.

Research and Development 98

Research and Development Treatment Media Medicine 98

Veriheal

MAY 31, 2022

According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. As patients became addicted to their pain meds and couldn’t secure refills, they began turning to illicit opioids like heroin and fentanyl. A Better Alternative for Chronic Pain.

Programs 52

Programs Chronic Pain Treatment Conditions 52

The Cannigma

MARCH 2, 2021

This issue is compounded when veterans do, on rare occasions, ask their doctors about medical marijuana, only to be treated as if they are mentally unstable or receive no specific health information at all,” the researchers found. This directly conflicts with past research claiming marijuana increases PTSD symptom severity.”.

Research and Development 143

Research and Development Treatment Chronic Pain Sleep 143

Cannabis Law Report

NOVEMBER 15, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments. “We Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

JULY 20, 2021

With our new psychedelic medicinal insurance solutions, business can access the necessary coverages to protect their business, attract qualified officers/directors, and bring new treatments to market.”. Eric Rahn, Managing Director. As with any niche industry still in its infancy, the risks are high.

Medicine 98

Medicine Business Research and Development Chronic Pain 98

Cannabis Law Report

OCTOBER 6, 2021

Under the terms of this agreement, Sinclair Research will perform preclinical animal studies including method, dosage and toxicity as part of the enabling trials for an Investigational New Drug Application (“IND”) for AnQlar, as required by the U.S. Food and Drug Administration (“FDA”). The studies are expected to begin in January of 2022.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Veriheal

MAY 3, 2022

A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Veriheal

AUGUST 31, 2021

Essay Summary: Sandeep conceptualizes a strain recommendation app in which consumers can create a profile and review strains and their effects (help with sleep, back pain, migraines, etc.). The app would also provide data to producers and distributors to identify trends in the market to better serve the needs of consumers. .

Research and Development 116

Research and Development Supply Chain Programs Education 116

The Cannigma

AUGUST 22, 2021

First things first, there is very little we know scientifically about the actual efficacy of cannabis tampons specifically, although there is a growing body of research on how cannabis, CBD, and THC can help treat menstrual pain and various gynecological conditions. Do cannabis tampons work? More on that below.).

THC 119

THC CBD Research and Development Conditions 119

Cannabis Law Report

JULY 13, 2021

Inhalation of cannabis extracts allows for a faster onset and higher bioavailability than tinctures and oils, and now that doctors can monitor a patient’s metered-dosage, more accurate patient data. Medical cannabis is a safer alternative to the conventional opiate solutions and other pain management treatments.

Extraction 105

Extraction Vaping Medicine Patients 105

Otherside Farms

JULY 4, 2022

Reduce Chronic Pain. CBC Isolate reduced osteoarthritis pain in 2011. In this study, researchers examined studied Bulk CBC Isolate and paw edema. The researchers studied adult mice neural stem progenitor cells (NSPCs) outside the body. With THC and CBD, CBC Isolate is the most effective depression treatment.

Research and Development 96

Research and Development Cannabinoids THC Concentrates 96

Cannabis Law Report

APRIL 4, 2019

House of Hemp hope to build on existing medical research and further explore the potential of cannabis as a healing plant. Limited evidence suggests cannabis can reduce nausea and vomiting during chemotherapy, improve appetite in people with HIV/AIDS, and reduce chronic pain and muscle spasms.

Cultivation 40

Cultivation Research and Development Chronic Pain Data 40

Cannabis Law Report

JULY 24, 2022

According to experts, research with psychedelics (also known as hallucinogens) or related substances will increase worldwide in the coming years. The market launch of drugs containing MDMA for post-traumatic stress disorder (PTSD) or psilocybin for the treatment of depression is expected in the next five to ten years [1].

Research and Development 52

Research and Development Legalization Treatment Patients 52

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 108

Programs Research and Development Education Treatment 108

Healer

APRIL 5, 2021

Does CBD help with pain? Among animal research, it’s clear that CBD can reduce pain and inflammation in various models of pain, including neuropathic pain, inflammatory pain, and arthritis-related pain.[1] How to use CBD for pain management.

CBD 98

CBD Chronic Pain Oil Topical 98

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”. Because it can cross the blood-brain barrier, MYMD-1 is also positioned to be a possible treatment for multiple sclerosis and other brain-related disorders. Chief Scientific Officer.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Healer

APRIL 5, 2021

Does CBD help with pain? Among animal research, it’s clear that CBD can reduce pain and inflammation in various models of pain, including neuropathic pain, inflammatory pain, and arthritis-related pain.[1] 1] Animal models, however, do not always translate to a human experience.

CBD 52

CBD Chronic Pain Oil Topical 52

Healer

APRIL 5, 2021

Does CBD help with pain? Among animal research, it’s clear that CBD can reduce pain and inflammation in various models of pain, including neuropathic pain, inflammatory pain, and arthritis-related pain.[1] 1] Animal models, however, do not always translate to a human experience.

CBD 52

CBD Chronic Pain Oil Topical 52

Sensi Seeds

JANUARY 4, 2019

Since 2001, Canadians seeking to use cannabis for medical treatment have had access to it under the Marihuana Medical Access Regulations (MMAR ). There is need for further research. Context of the Medicinal Cannabis Situation.

Medicine 75

Medicine Research and Development Patients Programs 75

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

NOVEMBER 24, 2021

Published by The Journal of Cannabis Research. At the same time, the outlook on cannabis research data is largely positive. Primary sources most frequently used in these reports are peer-reviewed journals or government reports, voices from medical associations or foundations, as well as government and university researchers.

Research and Development 52

Research and Development Medicine Access Media 52

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

Healer

JUNE 28, 2019

‘Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.’ Patients with advanced cancer who have pain that responds poorly to opioid therapy pose a clinical challenge. Abstract: Medical Study . ’ Abstract. Portenoy, Russell K.,

Cannabinoids 52

Cannabinoids THC Therapy Patients 52

Cannabis Law Report

MARCH 19, 2020

This advisory provides an overview of key regulatory activity and priorities that should be on the radar of any company engaged in the development or sale of products that contain CBD. In the absence of federal action, states have developed their own regulatory schemes. FDA submitted this report last week, as is discussed below.

CBD 45

CBD Research and Development Seed-To-Sale Data 45

Cannabis Law Report

OCTOBER 26, 2021

MyMD’s lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with autoimmune diseases including rheumatoid arthritis. MyMD’s lead drug candidate, MYMD-1, is being developed to target aging, aging-related diseases, and autoimmune diseases including rheumatoid arthritis. About MYMD-1.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

MAY 13, 2019

Researchers from the Queensland University of Technology conducted a wide-ranging review of 26 published studies across Australia, the United States, Canada and Ireland. Screening for relevancy, full-text review, data extraction, and risk of bias were completed by two independent investigators. Read More & Source: [link].

Medicine 45

Medicine Research and Development Clinical Trials Data 45